Australia's largest stock trading and investment forum Australia's #1 stock forum

GXY

0.00%

$5.28 galaxy resources limited

Galaxy: What I'd like to see..., page-26

First 26 Last

Share
Profile

Follow
killfeather

313 Posts.

548

09/06/17

11:56

Post #: 25194774
Share

Originally posted by vmp ↑

I'd like to see more sanity here.

We are producing at least 160,000 tonnes, equates to almost A$200m revenue at USD389/tonne cash costs excluding marketing exps, hence that's a gross margin of 57%. We know the opex is very low, hence we have a free cashflow of about $100 million p.a. This gives Gxy flexibility, having money to spend to increase mine life, or even acquire nemaska or other juniors.

The company has just provided a marketing/sales update 2 weeks ago, released an investor preso a week ago, provided answers to hc folks' questions at the AGM 3 weeks ago, provided update of further drilling to extend mine life. I wonder what more do we want in terms of update at the moment?

We know something big is going to happen this year. The company will announce a more clarified path forward - will we get debt funding or sell 30% etc of sdv. And China and the world will only need more lithium.

Obviously, there are other things affecting the market. If one is too rattled, cannot take the volatility or personally perceived risk hence unable to sleep or fear losing the family's fortune, then do whatever you think is right for you and your family that contributes to rationality in HC. If you need help, by all means, please reach out to the appropriate contacts or hotline. Life is more important than money.

Cheers

Expand

looks like we are just about to turn the corner
share price in the green at last !

GXY Price at posting: $1.98 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

AI stocks: What to expect in 2024-25